| 引用本文： |
-
徐雁,王玉红,林善丽,等.维持性血液透析患者血清铁调素水平与心血管疾病的关系[J].同济大学学报（医学版）,2016,37(2):82-86. [点击复制]
- XU Yan,WANG Yu-hong,LIN Shan-li,et al.Relationship of serum hepcidin with cardiovascular disease in maintenance hemodialysis patients[J].同济大学学报（医学版）,2016,37(2):82-86. [点击复制]
|
|
| 摘要: |
| 目的 探讨血清铁调素与维持性血液透析(maintenance hemodialysis, MHD)患者心血管疾病(cardiovascular disease, CVD)的关系。方法 稳定的MHD患者75例入选,年龄匹配的健康人20例为对照组。酶联免疫吸附法测定血清铁调素、晚期氧化蛋白产物(advanced oxidation protein products, AOPP)和IL-6。Spearman相关和线性回归分析铁调素与其他指标的相关性；二分类Logistic回归分析各指标与CVD的相关性。结果 MHD患者铁调素水平显著高于健康对照组[249.2(169.0~475.2)ng/ml vs 84.7(49.6~179.3)ng/ml,P＜0.05]。CVD患者铁调素水平明显高于无CVD者[335.9(206.3~514.2)ng/ml vs 210.5(133.6~392.3)ng/ml,P＜0.05]。Spearman相关分析显示铁调素与每周促红细胞生成素(EPO)剂量、EPO抵抗指数、铁蛋白、转铁蛋白饱和度、AOPP、高敏C反应蛋白、IL-6及左心室质量指数呈正相关,与血清前白蛋白、总铁结合力、不饱和铁结合力、转铁蛋白呈负相关。线性回归分析显示铁蛋白、总铁结合力、IL-6与铁调素水平独立相关。二分类Logistic回归分析显示铁调素升高为CVD发生的独立危险因素。结论 MHD患者血清铁调素水平与CVD相关,血清铁调素可能是MHD患者CVD新的标志物及治疗靶目标。 |
| 关键词: 铁调素 血液透析 心血管疾病 炎症 铁 |
| DOI：10.16118/j.1008-0392.2016.02.019 |
| 投稿时间：2015-06-24 |
| 基金项目: |
|
| Relationship of serum hepcidin with cardiovascular disease in maintenance hemodialysis patients |
| XU Yan,WANG Yu-hong,LIN Shan-li,YI Shao-na,GE Jun,HE Yan-bo |
| (Dept. of Nephrology, Yantai Hospital Affiliated to Binzhou Medical University, Yantai 264100, Shandong Province, China) |
| Abstract: |
| Objective To investigate serum hepcidin level and its relationship with cardiovascular disease(CVD) in maintenance hemodialysis(MHD) patients. MethodsBlood samples were obtained from 75 MHD patients before hemodialysis and 20 healthy subjects. Serum hepcidin, advanced oxidation protein products(AOPP) and IL-6 were measured by enzyme-linked immunosorbant assay(ELISA). Spearman correlation and linear regression analysis were used to assess the relationship between serum hepcidin and other parameters. Binary logistic regression analysis was used to assess the relationship between serum hepcidin level and other parameters and CVD in MHD patients. ResultsSerum hepcidin was significantly higher in MHD patients compared with controls [249.2(169.0-475.2)ng/ml vs. 84.7(49.6-179.3)ng/ml,P＜0.05], patients with CVD had higher serum hepcidin levels than those without CVD [335.9(206.3-514.2)ng/ml vs. 210.5(133.6-392.3)ng/ml, P＜0.05]. In MHD patients serum hepcidin level was correlated positively with weekly erythropoietin dose, erythropoietin resistance index, ferritin, transferin saturation, AOPP, high sensitive C reactive protein(hs-CRP), IL-6 and left ventricular mass index； and negatively correlated with serum pre-albumin, total iron-binding capacity, unsaturated iron-binding capacity and transferrin. Linear regression analysis showed that ferritin, total iron-binding capacity and IL-6 were associated hepcidin level. Binary logistic regression analysis showed that higher serum hepcidin level(＞249.2ng/ml) was positively and independently associated with CVD(OR=1.32, 95%CI 1.20-9.56, P=0.043). ConclusionSerum hepcidin level is associated with CVD in MHD patients, indicating that it might be a novel biomarker and therapeutic target for CVD. |
| Key words: hepcidin hemodialysis cardiovascular disease inflammation iron |
